Manufactures and markets custom folding cartons and mailers. Distributes nutritional and personal care products. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 1% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $20.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 5 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $23.9M against $20.8M in annual sales.
The stock sits at $0.72. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, DSS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DSS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.